UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers

Investigational new drugs, 2021-06, Vol.39 (3), p.785-795

2021

Volltextzugriff (PDF)

Preliminary results from TRITON2: A phase II study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations

Annals of oncology, 2018-10, Vol.29, p.viii272-viii272

2018

Volltextzugriff (PDF)

Genomic profiling of circulating tumour DNA (ctDNA) and tumour tissue for the evaluation of rucaparib in metastatic castration-resistant prostate cancer (mCRPC)

Annals of oncology, 2018-10, Vol.29, p.viii273-viii273

2018

Volltextzugriff (PDF)

Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad3-related (ATR) inhibitor in combination (combo) with carboplatin, olaparib or durvalumab in patients (pts) with advanced cancers

European journal of cancer (1990), 2016-12, Vol.69, p.S2-S2

2016

Volltextzugriff (PDF)

Rucaparib or Physician’s Choice in Metastatic Prostate Cancer

The New England journal of medicine, 2023-02, Vol.388 (8), p.719-732

2023

Volltextzugriff (PDF)

Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer

The New England journal of medicine, 2016-08, Vol.375 (5), p.443-453

2016

Volltextzugriff (PDF)

1603P Updated safety and efficacy of tazemetostat (TAZ) plus enzalutamide (ENZ) in patients with metastatic castration-resistant prostate cancer (mCRPC)

Annals of oncology, 2024-09, Vol.35, p.S967-S967

2024

Volltextzugriff (PDF)

1870TiP Tazemetostat in combination with a PARP Inhibitor or checkpoint inhibitor in patients (Pts) with solid tumors

Annals of oncology, 2021-09, Vol.32, p.S1254-S1254

2021

Volltextzugriff (PDF)

586P Safety of tazemetostat (TAZ) in combination with abiraterone/prednisone (A/P) or enzalutamide (E) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC)

Annals of oncology, 2021-09, Vol.32, p.S636-S636

2021

Volltextzugriff (PDF)

1648P Final clinical and liquid biopsy (LBx) results of phase II trial of sacituzumab govitecan (SG) in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) progressing on androgen receptor signaling inhibitors (ARSI)

Annals of oncology, 2024-09, Vol.35, p.S993-S994

2024

Volltextzugriff (PDF)

1406P Interim results of a phase II trial of sacituzumab govitecan (SG) in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) progressing on androgen receptor signaling inhibitors (ARSI)

Annals of oncology, 2022-09, Vol.33, p.S1188

2022

Volltextzugriff (PDF)

The double discontinuous mode operation of a converter: a method for soft switching

IEEE transactions on power electronics, 2004-03, Vol.19 (2), p.453-460

2004

Volltextzugriff (PDF)

598P A phase Ib study of enzalutamide (Enza) plus CC-115 in men with metastatic castration-resistant prostate cancer (mCRPC)

Annals of oncology, 2021-09, Vol.32, p.S643-S644

2021

Volltextzugriff (PDF)

659P Rucaparib population pharmacokinetics (PPK) and exposure-response (ER) analyses in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in TRITON2

Annals of oncology, 2020-09, Vol.31, p.S533-S534

2020

Volltextzugriff (PDF)

Guidelines for Management of Treatment-Emergent Adverse Events During Rucaparib Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer

Cancer management and research, 2022-01, Vol.14, p.673-686

2022

Volltextzugriff (PDF)

846PD - Preliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): Updated analyses

Annals of oncology, 2019-10, Vol.30, p.v327-v328

2019

Volltextzugriff (PDF)

Preliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): Updated analyses

Annals of oncology, 2019-10, Vol.30, p.v327-v328

2019

Volltextzugriff (PDF)

846PDPreliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): Updated analyses

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

795PDGenomic profiling of circulating tumour DNA (ctDNA) and tumour tissue for the evaluation of rucaparib in metastatic castration-resistant prostate cancer (mCRPC)

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

793PDPreliminary results from TRITON2: A phase II study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

1LBA - Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad3-related (ATR) inhibitor in combination (combo) with carboplatin, olaparib or durvalumab in patients (pts) with advanced cancers

European journal of cancer (1990), 2016-12, Vol.69, p.S2-S2

2016

Volltextzugriff (PDF)

The TRITON clinical trial programme: Evaluation of the PARP inhibitor rucaparib in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD)

Annals of oncology, 2017-09, Vol.28, p.v291-v291

2017

Volltextzugriff (PDF)

cROVER: Improving ROVER using automatic error detection

2011 IEEE International Conference on Acoustics, Speech and Signal Processing (ICASSP), 2011, p.1753-1756

2011

Volltextzugriff (PDF)

Minimization of conduction losses in the boost converter with galvanic isolation

IEE conference publication, 2001, p.334-340

2001

Volltextzugriff (PDF)

Dexamethasone−Methotrexate: An Efficient Chemical Inducer of Protein Dimerization In Vivo

Journal of the American Chemical Society, 2000-05, Vol.122 (17), p.4247-4248

2000

Volltextzugriff (PDF)

1 – 25 von 123

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(111)
Mit Volltextzugriff
(102)

Publikationsform

Artikel
(117)
Tagungsberichte
(6)

Sprache

Englisch
(121)
Französisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers

Preliminary results from TRITON2: A phase II study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations

Genomic profiling of circulating tumour DNA (ctDNA) and tumour tissue for the evaluation of rucaparib in metastatic castration-resistant prostate cancer (mCRPC)

Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad3-related (ATR) inhibitor in combination (combo) with carboplatin, olaparib or durvalumab in patients (pts) with advanced cancers

Rucaparib or Physician’s Choice in Metastatic Prostate Cancer

Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer

1603P Updated safety and efficacy of tazemetostat (TAZ) plus enzalutamide (ENZ) in patients with metastatic castration-resistant prostate cancer (mCRPC)

1870TiP Tazemetostat in combination with a PARP Inhibitor or checkpoint inhibitor in patients (Pts) with solid tumors

586P Safety of tazemetostat (TAZ) in combination with abiraterone/prednisone (A/P) or enzalutamide (E) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC)

1648P Final clinical and liquid biopsy (LBx) results of phase II trial of sacituzumab govitecan (SG) in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) progressing on androgen receptor signaling inhibitors (ARSI)

1406P Interim results of a phase II trial of sacituzumab govitecan (SG) in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) progressing on androgen receptor signaling inhibitors (ARSI)

The double discontinuous mode operation of a converter: a method for soft switching

598P A phase Ib study of enzalutamide (Enza) plus CC-115 in men with metastatic castration-resistant prostate cancer (mCRPC)

659P Rucaparib population pharmacokinetics (PPK) and exposure-response (ER) analyses in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in TRITON2

Guidelines for Management of Treatment-Emergent Adverse Events During Rucaparib Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer

846PD - Preliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): Updated analyses

Preliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): Updated analyses

846PDPreliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): Updated analyses

795PDGenomic profiling of circulating tumour DNA (ctDNA) and tumour tissue for the evaluation of rucaparib in metastatic castration-resistant prostate cancer (mCRPC)

793PDPreliminary results from TRITON2: A phase II study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations

1LBA - Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad3-related (ATR) inhibitor in combination (combo) with carboplatin, olaparib or durvalumab in patients (pts) with advanced cancers

The TRITON clinical trial programme: Evaluation of the PARP inhibitor rucaparib in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD)

cROVER: Improving ROVER using automatic error detection

Minimization of conduction losses in the boost converter with galvanic isolation

Dexamethasone−Methotrexate: An Efficient Chemical Inducer of Protein Dimerization In Vivo

Suchergebnisse filtern